Cargando…
Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects 5–8 million people in Latin America. Although the nitroheterocyclic compound benznidazole has been the front-line drug for several decades, treatment failures are common. Benznidazole is a pro-drug and is bio-activated...
Autores principales: | Campos, Mônica C., Phelan, Jody, Francisco, Amanda F., Taylor, Martin C., Lewis, Michael D., Pain, Arnab, Clark, Taane G., Kelly, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663738/ https://www.ncbi.nlm.nih.gov/pubmed/29089615 http://dx.doi.org/10.1038/s41598-017-14986-6 |
Ejemplares similares
-
Mixed infections in genotypic drug-resistant Mycobacterium tuberculosis
por: Wang, Linfeng, et al.
Publicado: (2023) -
Optical Absorption of the Antitrypanocidal Drug Benznidazole in Water
por: Bezerra, Eveline M., et al.
Publicado: (2014) -
Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole
por: Téllez, Jair, et al.
Publicado: (2019) -
Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis
por: Napier, Gary, et al.
Publicado: (2023) -
Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance
por: Oppong, Yaa E. A., et al.
Publicado: (2019)